An interventional study of Gemigliptin and Placebo in Type 2 Diabetes Mellitus, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-21.
Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. gemigliptin · Diabetes Mellitus, Type 2.
Among the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment, is one of 5 that started in 2014, is the only one with no phase, and was the 8th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 130 across the 18 interventional studies. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 4 most frequent:
Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
15 studies in Diabetes Mellitus, Type 2 by Seoul National University Hospital: 1 open now, 1 under way, none of them phase 3. Of 10 finished, 1 (10%) have results posted.
Among the 15 studies in Diabetes Mellitus, Type 2 by Seoul National University Hospital, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2014, is one of 6 with no phase, and was the 4th registered.
Seoul National University Hospital’s Diabetes Mellitus, Type 2 studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Seoul National University Hospital’s 15 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an exploratory study on the metabolic endotoxemia associated with type 2 diabetes. The investigators will measure systemic endotoxin level and lipid level after ingestion of high fat diet to evaluate the effect of gemigliptin, a DPP-4 inhibitor, on metabolic endotoxemia and lipemia induced by high fat diet.
Study subjects will be allocated to either gemigliptin or placebo. After 4 weeks of treatment and 2 weeks of wash out period, all subjects will be switched to the opposite arm.
The subjects will be tested oral fat tolerance test and adipose tissue needle biopsy(only for the subjects who agreed to participate donate adipose tissue) at 3 time points: the start of 1st treatment, end of 1st treatment and end of 2nd treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gemigliptin 50mg qd added to subjects current diabetes treatment
Drug: Gemigliptin
Placebo (identical in appearance to gemigliptin)
Drug: Placebo
Also known as: Zemiglo
Difference between baseline and peak serum LPS
The increment of serum LPS after ingestion of high fat diet
Time frame: serum LPS before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet
Fasting serum LPS level
Compare fasting LPS level between treatment group
Time frame: After 10 hrs of fasting
Incremental AUC of serum LPS during oral fat tolerance test
Calculated incremental AUC of serum LPS
Time frame: serum LPS before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet
Difference between baseline and peak serum triglyceride level
The increment of serum TG after ingestion of high fat diet
Time frame: serum TG before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet
Incremental AUC of serum triglyceride level during oral fat tolerance test
Calculated incremental AUC of serum TG
Time frame: serum TG before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet
Difference between baseline and peak serum apolipoprotein-B48
The increment of serum apolipoprotein-B48 after ingestion of high fat diet
Time frame: serum apolipoprotein-B48 before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet
Incremental AUC of serum apolipoprotein-B48 during oral fat tolerance test
Calculated incremental AUC of serum apolipoprotein-B48
Time frame: serum apolipoprotein-B48 before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet
Serum level of inflammatory markers (CRP, TNF-alpha, IL-6)
Compare serum level of inflammatory markers between treatment groups
Time frame: After 10 hr of fasting
mRNA expression level of inflammatory markers in the adipose tissue
Compare mRNA expression level of inflammatory markers
Time frame: After high fat diet ingestion
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jul 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemigliptin
Seoul National University Hospital →